Jonathan Wright, MD
Urology · Seattle, WANPI 1336250752
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,083 of the $3,707 with a category attached, or 83.2%. Sanofi accounts for 86.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $3,442 and has fallen 96.7% since, to $115 in 2025.
Across 9 payments — averaging $411.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Photocure Inc$171
- Astellas Pharma US Inc$115
- Coloplast$75
- Dendreon Pharmaceuticals LLC$58
- Ferring Pharmaceuticals Inc.$33
- plus $42 from 2 others
Across 50 payments — averaging $20,016 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$715K
- Pfizer$194K
- Seagen Inc.$52K
- E.r. Squibb & Sons, L.L.C.$32K
- Janssen Research & Development, LLC$8K
What the payments were for
- Consulting fees$3,08383%
- Food & beverage$54915%
- Education$752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $3,213 |
| Photocure Inc | 1 | $171 |
| Astellas Pharma US Inc | 1 | $115 |
| Coloplast | 1 | $75 |
| Dendreon Pharmaceuticals LLC | 1 | $58 |
| Ferring Pharmaceuticals Inc. | 1 | $33 |
| 180 Medical, Inc. | 1 | $29 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,707 in reported general payments places this provider in the 65th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 62 | $1,097 |
| Finasteride | 66 | $794 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 13 | $785 |
| Dutasteride | 11 | $368 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Other urology in Seattle
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Vi NguyenSeattle$53K
- Rogerio HuangSeattle$45K
- Cristopher GarlitzSeattle$45K
- Sarah PsutkaSeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.